Incidence Prevalence Predictors Risk factors and Assessment Criteria for Chemotherapy Induced Peripheral Neuropathy CIPN A Systematic Review and Meta Analysis

Abstract

ABSTRACT newline Incidence, Prevalence, Predictors, Risk Factors and Assessment Criteria for Chemotherapy Induced Peripheral Neuropathy (CIPN): a systematic review and meta- analysis newlineBackground of study newline newlineChemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of many chemotherapeutic agents and a major cause of ongoing pain in cancer survivors. Severe acute CIPN may require chemotherapy dose reduction or cessation. There is no effective CIPN prevention strategy; treatment of established chronic CIPN is limited, and the prevalence of CIPN is not known. newlineObjectives of the study newline newline1. To determine the incidence and prevalence of chemotherapy induced peripheral neuropathy in adult population. newline2. To identify the predictors and risk factors of chemotherapy induced peripheral neuropathy in adult population. newline3. To find out various assessment criteria used on adult patients for chemotherapy induced peripheral neuropathy. newlineResearch Methodology newline newlineHere the systematic review was used to identify studies reporting the prevalence of CIPN. Researcher searched Delnet, RemoteXS (PGIMER), Ebsco, Willey online library, Medline, PubMed, and Web of Knowledge for relevant references and used random-effects meta-regression to estimate overall prevalence. Study quality assessed by using the CONSORT and STROBE guidelines, and report findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. newline newline newline newlineConclusion and Results newline newlineThe present systematic review included 133 studies with data from 12,378 patients in the meta-analysis. CIPN aggregate prevalence was 49.6%, 41.45% when measured in the first year after chemotherapy, 29.0% at 2-5 years and 6%-16% at 6-10 years and more than 10 years. Different chemotherapy drugs were associated with differences in CIPN prevalence, and there was some evidence of publication bias. A qualitative summary of factors reported to alter the risk of CIPN also provided. Genetic risk factors were reported in 18 studies. Clinical risk factors, identified in 38 studies,